Authors of a retrospective analysis, published in Annals of Internal Medicine on July 9, 2024, looked at the rates of major hemorrhagic and ischemic events in patients with cirrhosis who were newly prescribed apixaban and compared them with patients who were prescribed rivaroxaban or warfarin for the treatment of AFib.